Rexahn Pharmaceuticals Inc. (RNN)

1.59
0.15 8.60
AMEX : Health Technology
Prev Close 1.74
Open 1.75
Day Low/High 1.58 / 1.75
52 Wk Low/High 1.42 / 3.19
Volume 383.11K
Avg Volume 322.80K
Exchange AMEX
Shares Outstanding 31.74M
Market Cap 56.19M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Rexahn Reports Data From The Ongoing Phase 2a Clinical Trial Of RX-3117 In Advanced Bladder Cancer At The American Society Of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting

Rexahn Reports Data From The Ongoing Phase 2a Clinical Trial Of RX-3117 In Advanced Bladder Cancer At The American Society Of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting

Encouraging Progression Free Survival and Evidence of Tumor Shrinkage Observed in Patients with Advanced Bladder Cancer Who Had Failed on Multiple Prior Treatments Including Immunotherapy and Gemcitabine

Rexahn Pharmaceuticals Receives Notice Of Allowance For A New U.S. Patent Covering The Use Of RX-5902 (Supinoxin™)

Rexahn Pharmaceuticals Receives Notice Of Allowance For A New U.S. Patent Covering The Use Of RX-5902 (Supinoxin™)

Patent Protection for RX-5902 (Supinoxin™) Extended until 2036 for Multiple Cancers including Triple Negative Breast Cancer

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From The Ongoing Phase IIa Clinical Trial Of RX-3117 In Advanced Bladder Cancer At The 2017 European Society For Medical Oncology (ESMO) Congress

Rexahn Pharmaceuticals Presents Preliminary Efficacy Data From The Ongoing Phase IIa Clinical Trial Of RX-3117 In Advanced Bladder Cancer At The 2017 European Society For Medical Oncology (ESMO) Congress

RX-3117 Monotherapy Increased Progression Free Survival and Showed Evidence of Tumor Shrinkage in Patients with Advanced Bladder Cancer Resistant to Gemcitabine who had failed on Multiple Prior Treatments

Rexahn Pharmaceuticals Receives New U.S. Patent For Supinoxin™

Rexahn Pharmaceuticals Receives New U.S. Patent For Supinoxin™

Patent Protection Extended until 2034

Rexahn Pharmaceuticals Receives Notice Of Allowance For A New U.S. Patent Covering The Use Of RX-3117

Rexahn Pharmaceuticals Receives Notice Of Allowance For A New U.S. Patent Covering The Use Of RX-3117

Patent Protection for RX-3117 Extended until 2036